The stock of Black Diamond Therapeutics Inc (NASDAQ:BDTX) last traded at $2.57, up 4.05% from the previous session.
BDTX stock price is now -22.97% away from the 50-day moving average and -46.70% away from the 200-day moving average. The market capitalization of the company currently stands at $145.43M.
With the price target of $20, Raymond James recently initiated with Outperform rating for Black Diamond Therapeutics Inc (NASDAQ: BDTX). , while ‘Stifel’ rates the stock as ‘Buy’
In other news, Versant Venture Capital VI, L., 10% Owner sold 221,600 shares of the company’s stock on Aug 28 ’24. The stock was sold for $1,400,556 at an average price of $6.32. Upon completion of the transaction, the 10% Owner now directly owns 3,726,341 shares in the company, valued at $9.58 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 31 ’24, Former Employer David Epstein bought 50,000 shares of the business’s stock. A total of $310,000 was incurred on buying the stock at an average price of $6.20. A total of 24.20% of the company’s stock is owned by insiders.
During the past 12 months, Black Diamond Therapeutics Inc has had a low of $2.15 and a high of $7.66. As of last week, the company has a debt-to-equity ratio of 0.24, a current ratio of 5.55, and a quick ratio of 5.55. The fifty day moving average price for BDTX is $3.3796 and a two-hundred day moving average price translates $4.82935 for the stock.
The latest earnings results from Black Diamond Therapeutics Inc (NASDAQ: BDTX) was released for 2024-09-30.
